Entrada Therapeutics’ (TRDA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Entrada Therapeutics (NASDAQ:TRDA) in a research report report published on Wednesday morning,Benzinga reports. The firm currently has a $20.00 price objective on the stock.

A number of other research analysts also recently commented on TRDA. Guggenheim raised shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Weiss Ratings reissued a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Monday, December 29th. Roth Mkm set a $13.00 target price on Entrada Therapeutics in a research report on Thursday, November 6th. Finally, Oppenheimer started coverage on Entrada Therapeutics in a research report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.50.

Entrada Therapeutics Trading Down 1.1%

Shares of Entrada Therapeutics stock opened at $11.29 on Wednesday. The stock’s fifty day moving average price is $10.83 and its 200-day moving average price is $8.23. The firm has a market cap of $431.50 million, a P/E ratio of -4.53 and a beta of -0.12. Entrada Therapeutics has a 12 month low of $4.93 and a 12 month high of $13.82.

Institutional Investors Weigh In On Entrada Therapeutics

A number of large investors have recently made changes to their positions in the stock. AlphaQuest LLC grew its stake in Entrada Therapeutics by 239.8% during the 2nd quarter. AlphaQuest LLC now owns 39,625 shares of the company’s stock valued at $266,000 after purchasing an additional 27,963 shares during the last quarter. Corton Capital Inc. purchased a new position in Entrada Therapeutics during the 2nd quarter worth approximately $193,000. Los Angeles Capital Management LLC lifted its stake in Entrada Therapeutics by 60.6% during the 2nd quarter. Los Angeles Capital Management LLC now owns 44,632 shares of the company’s stock valued at $300,000 after acquiring an additional 16,840 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Entrada Therapeutics by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock valued at $4,245,000 after acquiring an additional 42,479 shares during the last quarter. Finally, Intech Investment Management LLC increased its stake in shares of Entrada Therapeutics by 15.7% in the second quarter. Intech Investment Management LLC now owns 17,702 shares of the company’s stock worth $119,000 after acquiring an additional 2,397 shares during the period. 86.39% of the stock is owned by hedge funds and other institutional investors.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.